
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's fourth quarter results were encouraging, with Jakafi generating $773 million, surpassing expectations due to strong demand trends and limited competition impact. The firm's recent approval of Opzelura has shown promising efficacy in treating atopic dermatitis and chronic prurigo, which contributes to a positive outlook for Incyte's growth trajectory. Analysts view Incyte's existing commercial legacy business as a solid revenue foundation, complemented by a promising pipeline that may offset challenges such as the upcoming Jakafi patent cliff in 2028, suggesting sustained growth potential of approximately 5%-7%.
Bears say
Incyte faces significant financial challenges primarily due to eroding pricing power for its leading drug Jakafi and the potential for poor performance from its earlier-stage pipeline, raising concerns about the viability of future revenue streams. The company is also at risk of slowed adoption of its marketed drugs, difficulties in extending Jakafi's life cycle, and increased competition that could further impact sales growth. Additionally, the lack of compelling clinical data for its drugs, alongside potential safety concerns and pricing pressures, could adversely affect investor confidence and negatively influence the stock's performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares